Amgen Shares Decline on Kissei's Tavneos Liver Risk Warning

Amgen shares fell after Japanese drugmaker Kissei issued a warning about the risk of liver damage associated with its drug Tavneos. Kissei released a safety notice stating that serious liver side effects may occur with the use of Tavneos. This has raised concerns about drugs in Amgen's portfolio that contain the same active ingredient. Tavneos is used to treat vasculitis and holds a significant place in Amgen's product range in this area. Kissei's warning has created questions about the drug's safety profile, making investors uneasy about potential regulatory actions and possible declines in sales revenue. Amgen shares dropped over 2% in pre-market trading following the news. Analysts note that this warning could pressure Amgen's short-term stock performance, but the long-term impact may be limited due to the company's broad drug portfolio and strong R&D pipeline. However, if more details about the liver risk emerge, regulators could take additional measures, potentially affecting the drug's market share. Investors are closely monitoring Amgen's official statements on the matter and any regulatory developments. The company's position on the current safety data for Tavneos and its response to Kissei's warning will be key to the stock's future trajectory. This is not investment advice.